The identification and study of proresolving lipid mediators of inflammation resolution has long been initiated. However, the paradigm shifts towards how we now understand the pathogenesis and treatment of several prevalent and harmful diseases have only occurred about fifteen years ago, with the recognition of inflammation as a central mechanism in the pathophysiology of diseases and with the uncovering of an active resolution of inflammation response. These concept changes have boosted inflammation research, revealing a large family of specialized proresolving mediators (SPMs), such as lipoxins, resolvins, protectins and maresins, with an ever-expanding evidence of protective effects. Benefits do not appear to be limited to their potent proresolving and anti-inflammatory actions, also including protective effects on adaptive immunity, redox status, endothelial function, cell proliferation/migration and pain. More recently, interesting clues of their interrelationship with the renin-angiotensin-aldosterone system or of their putative neuromodulatory effects (for example through their interaction with the endocannabinoid system and other central neurotransmitters) highlight even more their therapeutic potential in cardiometabolic or neurological and psychiatric disorders.
The main goal of this Research Topic (RT) is to improve the knowledge on the role of SPMs and their receptors in cardiometabolic, neurological and psychiatric disorders, gathering the scientific evidence on the pleiotropic effects elicited by these lipid mediators and shedding light on their therapeutic potential.
Original Research Articles, Brief Research Reports, Reviews or Mini-Reviews are types of manuscript of interest. The scope of this RT includes the fields of cardiometabolic, neurological and psychiatric disorders, addressing one or more of the following pathways elicited by SPMs:
- proresolving and anti-inflammatory mechanisms;
- modulation of oxidative stress;
- regulation of endothelial function;
- modulation of adaptive immunity;
- regulation of cell proliferation and migration;
- inhibition of angiotensin-converting enzyme (ACE)/angiotensin II (Ang II)/angiotensin II type 1 receptor (AT1R) axis/ stimulation of angiotensin converting enzyme 2 (ACE2)/angiotensin 1-7/Mas receptor axis;
- modulation of pain and neuroinflammation;
- neuromodulation (e.g. allosteric modulation; interference with neurotransmitter synthesis, release or degradation; synaptic plasticity).
The identification and study of proresolving lipid mediators of inflammation resolution has long been initiated. However, the paradigm shifts towards how we now understand the pathogenesis and treatment of several prevalent and harmful diseases have only occurred about fifteen years ago, with the recognition of inflammation as a central mechanism in the pathophysiology of diseases and with the uncovering of an active resolution of inflammation response. These concept changes have boosted inflammation research, revealing a large family of specialized proresolving mediators (SPMs), such as lipoxins, resolvins, protectins and maresins, with an ever-expanding evidence of protective effects. Benefits do not appear to be limited to their potent proresolving and anti-inflammatory actions, also including protective effects on adaptive immunity, redox status, endothelial function, cell proliferation/migration and pain. More recently, interesting clues of their interrelationship with the renin-angiotensin-aldosterone system or of their putative neuromodulatory effects (for example through their interaction with the endocannabinoid system and other central neurotransmitters) highlight even more their therapeutic potential in cardiometabolic or neurological and psychiatric disorders.
The main goal of this Research Topic (RT) is to improve the knowledge on the role of SPMs and their receptors in cardiometabolic, neurological and psychiatric disorders, gathering the scientific evidence on the pleiotropic effects elicited by these lipid mediators and shedding light on their therapeutic potential.
Original Research Articles, Brief Research Reports, Reviews or Mini-Reviews are types of manuscript of interest. The scope of this RT includes the fields of cardiometabolic, neurological and psychiatric disorders, addressing one or more of the following pathways elicited by SPMs:
- proresolving and anti-inflammatory mechanisms;
- modulation of oxidative stress;
- regulation of endothelial function;
- modulation of adaptive immunity;
- regulation of cell proliferation and migration;
- inhibition of angiotensin-converting enzyme (ACE)/angiotensin II (Ang II)/angiotensin II type 1 receptor (AT1R) axis/ stimulation of angiotensin converting enzyme 2 (ACE2)/angiotensin 1-7/Mas receptor axis;
- modulation of pain and neuroinflammation;
- neuromodulation (e.g. allosteric modulation; interference with neurotransmitter synthesis, release or degradation; synaptic plasticity).
